310 Mira Street, Stavropol, Russia, 355017
+7 865 2352511, +7 865 2353229.
The journal is included into The list of leading scientific periodicals.
Ol'ga Vladimirovna Karapetyan; Irina Ivanovna Fomochkina; Evgeniya Yurievna Zyablitskaya; Vladimir Anatolievich Kubyshkin; Evgeniya Pavlovna Kovalenko; Polina Gennadevna Korobova; Tatiana Pavlovna Makalish; Anatoly Vladimirovich Kubyshkin;
The analysis of the state of local markers of inflammation and apoptosis factors in the endometrium in case of endometrial hyperplasia (EH) of various types in 89 patients of fertile age was carried out. There was shown the prevalence of a nonspecific inflammatory reaction with an increase in the expression of total leukocyte antigen (CD45), most pronounced in atypical hyperplasia, against the background of the absence of obvious changes in the population of natural killer cells (CD56), phagocytic activity of tissue macrophages (CD68) and cytotoxic T-lymphocytes (CD8a). An increase in nonspecific inflammation was confirmed by the activation of pro-inflammatory cytokines in uterine washes and an increase in proteolytic activity (trypsin- and elastase-like activity) against the background of a decrease in the inhibitory potential (antitryptic activity and, especially, acid-stable inhibitors). An increase in the inflammatory response in the endometrium in atypical hyperplasia was accompanied by a decrease in the expression of CD95, which indicates a parallel decrease in the readiness of endometrial cells for apoptosis. An increase in nonspecific inflammation and a decrease in readiness for apoptosis may be factors contributing to the formation of endometrial adenocarcinoma.
1. Travaglino A., Raffone A., Saccone G., Mollo A., De Placido G. [et al.]. Endometrial hyperplasia and the risk of coexistent cancer: WHO versus EIN criteria.Histopathology. 2019;74(5):676-687. https://doi.org/10.1111/his.13776
2. Sobczuk K., Sobczuk A. New classification system of endometrial hyperplasia WHO 2014 and its clinical implications. Przegla̜ d Menopauzalny. 2017;16(3):107-11. https://doi.org/10.5114/pm.2017.70589
3. Selen S., Kilic F., Comert G. K., Unsal M., Kilic C. [et al.]. Can preoperative inflammatory markers differentiate endometrial cancer from complex atypical hyperplasia/endometrial intraepithelial neoplasia? The Journal of Obstetrics and Gynaecology Research. 2020;46(7):1148-1156. https://doi.org/10.1111/jog.14314
4. Sanderson P. A., Critchley H. O., Williams A. R., Arends M. J., Saunders P. T. New concepts for an old problem: the diagnosis of endometrial hyperplasia. Human Reproduction Update. 2017;23(2):232-254. https://doi.org/10.1093/humupd/dmw042
5. Travaglino A., Raffone A., Saccone G., Insabato L., Mollo A. [et al.]. Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: A systematic review. Acta Obstetricia Gynecologica Scandinavica. 2019;98(9):1086-1099. https://doi.org/10.1111/aogs.13587
6. Mutter G. L., Zaino R. G., Baak J. P, Bentley R. S., Robboy S. J. Benign endometrial hyperplasia sequence and endometrial intraepithelial neoplasia. International Journal of Gynecological Pathology. 2007;26(2):103-114. https://doi.org/10.1097/pgp.0b013e31802e4696
7. Trimble C. L., Method M., Leitao M., Lu K., Loffe O. [et al.]. Management of endometrial precancers. Obstetrics and Gynecology. 2012;120(5):1160-1175. https://doi.org/10.1097/aog.0b013e31826bb121
8. Kubyshkin A. V., Aliev L. L., Fomochkina I. I., Kovalenko Ye. P., Litvinova S. V. Endometrial hyperplasia-related inflammation: its role in the development and progression of endometrial hyperplasia. Inflammation Research. 2016;65(10):785-794. https://doi.org/10.1007/s00011-016-0960-z
9. Ethier J. L., Desautels D. N., Templeton A. J., Oza A., Amir E., Lheureux S. Is the neutrophil-to-lymphocyte ratio prognostic of survival outcomes in gynecologic cancers? A systematic review and meta-analysis. Gynecologic Oncology. 2017;145:584-594. https://doi.org/10.1016/j.ygyno.2017.02.026
10. Kokawa K., Shikone T., Otani T., Nishiyama R., Ishii Y. [et al.]. Apoptosis and the expression of Bax and Bcl-2 in hyperplasia and adenocarcinoma of the uterine endometrium. Human Reproduction. 2001;16:2211-2218. https://doi.org/10.1093/humrep/16.10.2211
11. Steinbakk A., Gudlaugsson E., Aasprong O. G., Skaland I., Malpica A. [et al.]. Molecular biomarkers in endometrial hyperplasias predict cancer progression. American Journal of Obstetrics & Gynecology. 2011;204(4):357.e1-12. https://doi.org/10.1016/j.ajog.2010.12.007
12. Zhdanov A. V., Sukhikh G. T., Davydova M. P., Slukina T. V., Chernukha G. E., Samoilova T. E. Correlations in the cytokine system in endometrial hyperplasia. Bulletin of Experimental Biology and Medicine. 2003;136(3):270-272. https://doi.org/10.1023/b:bebm.0000008980.25653.1b
13. Mc Campbell A. S., Broaddus R. R., Loose D. S., Davies P. J. Overexpression of the insulin-like growth factor I receptor and activation of the AKT pathway in hyperplastic endometrium. Clinical Cancer Research. 2006;12:6373-6378. https://doi.org/10.1158/1078-0432.ccr-06-0912
14. Sukhikh G. T., Zhdanov A. V., Davydova M. P., Slukina T. V., Chernukha G. E., Samoilova T. E. Disorders in cytokine gene expression in endometrial hyperplasia and effect of hormone therapy. Bulletin of Experimental Biology and Medicine. 2005;139:235-237. https://doi.org/10.1007/s10517-005-0257-7
Keywords: inflammation, carcinogenesis, apoptosis, markers, proteinases, cytokines, growth factors, endometrial hyperplasia, macrophages